Salivary duct carcinoma with neuroendocrine features: Report of a case with cytological and immunohistochemical study

Diagnostic Cytopathology

Volumn 31, Issue 3, 2004, Pages 189-192

  Laforga, Juan B ^a  

^a HOSPITAL MARINA ALTA   (Spain)

Author keywords

Androgen receptor; Endocrine differentiation; Immunostaining; Oncocytic like; Salivary duct carcinoma

Indexed keywords

ANDROGEN RECEPTOR; CHROMOGRANIN A; CYTOKERATIN; CYTOKERATIN 20; CYTOKERATIN 7; CYTOKERATIN AE1; CYTOKERATIN AE3; DNA TOPOISOMERASE (ATP HYDROLYSING) A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GENE PRODUCT; GROSS CYSTIC DISEASE FLUID PROTEIN 15; HEMATOXYLIN; KI 67 ANTIGEN; MITOCHONDRION ANTIBODY; PHOSPHOTUNGSTIC ACID; PROGESTERONE RECEPTOR; PROTEIN P53; PROTEIN S 100; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

AGED; ANTIGEN DETECTION; ARTICLE; ASPIRATION BIOPSY; CANCER CYTODIAGNOSIS; CANCER RADIOTHERAPY; CASE REPORT; CELL DIFFERENTIATION; CLINICAL FEATURE; CYTOPATHOLOGY; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; NEUROENDOCRINE DISEASE; PAROTID GLAND CARCINOMA; PAROTIDECTOMY; PRIORITY JOURNAL; SALIVARY GLAND DUCT; SALIVARY GLAND DUCT CARCINOMA; STAINING;

AGED; BIOPSY, FINE-NEEDLE; CARCINOMA, NEUROENDOCRINE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; PAROTID NEOPLASMS;

EID: 4344647925     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/dc.20096     Document Type: Article

References (30)

1. Kleinsasser O, Klein HJ, Hubner G. Speichelgangcarcinome: ein den Milchgangcarcinomen der Brustdruse analoge Gruppe von Speicheldrusentumoren. Arch Klin Exp Ohren Nasen Kehlkopfheilkd 1968; 192:100-105.
2. Hui KK, Batsakis JG, Luna MA, Mackay B, Byers RM. Salivary duct adenocarcinoma: a high grade malignancy. J Laryngol Otol 1986;100: 105-114.
3. Delgado R, Vuitch F, Albores-Saavedra J. Salivary duct carcinoma. Cancer 1993;72:1503-1512.
4. Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD. Salivary duct carcinoma: clinicopathologic and immunohistochemical review of 26 cases. Cancer 1996;77:223-230.
5. Zohar Y, Shem-Tov Y, Gal R. Salivary duct carcinoma in major and minor salivary glands. J Craniomaxillofac Surg 1988;16:320-323.
6. Domson KK, Wakely PE Jr. Aspiration and imprint cytopathology of salivary duct carcinoma. Cancer 1997;81:281-286.
7. Fýrat P, Cramer H, Feczko JD, et al. Fine-needle aspiration biopsy of salivary duct carcinoma: report of five cases. Diagn Cytopathol 1997; 16:526-530.
8. García-Bonafe M, Catala I, Tarragona J, Tallada N. Cytologic diagnosis of salivary duct carcinoma: a review of seven cases. Diagn Cytopathol 1998;19:120-123.
9. Gilcrease MZ, Guzman-Paz M, Froberg K, Pambuccian S. Salivary duct carcinoma: is a specific diagnosis possible by fine needle aspiration cytology? Acta Cytol 1998;42:1389-1396.
10. Klijanienko J, Vielh P. Cytologic characteristics and histomorphologic correlations of 21 salivary duct carcinomas. Diagn Cytopathol 1998; 19:333-337.
11. Bradwein MS, Huvos AG. Oncocytic tumors of major salivary glands: a study of 68 cases with follow-up of 44 patients. Am J Surg Pathol 1991:15:514-528.
12. Laforga JB, Aranda FI. Oncocytic carcinoma of parotid gland: fine-needle aspiration and histologic findings. Diagn Cytopathol 1994;11: 376-379.
13. Hui KK, Luna MA, Batsakis JG, Ordoñez NG, Weber R. Undifferentiated carcinomas of the major salivary glands. Oral Surg Oral Med Oral Pathol 1990:69:76-83.
14. Simpson RHW, Clarcke TJ, Sarsfield PTL, Babajews AV. Salivary duct adenocarcinoma. Histopathology 1991:18:229-235.
15. James GK, Pudek M, Berean KW, Diamandis EP, Archibald BL. Salivary duct carcinoma secreting prostate-specific antigen. Am J Clin Pathol 1996;106:242-247.
16. Kapadia SB, Barnes L. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol 1998;11:1033-1038.
17. Wick MR, Ockner DM, Mills SE, Ritter JH, Swanson PE. Homologous carcinomas of the breasts, skin, and salivary glands: a histological and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma, and salivary duct carcinoma. Am J Clin Pathol 1998;109:75-84.
18. Pagani A, Sapino A, Eusebi V, Bergnolo G, Bussolati G. PIP/GC-DFP-15 gene expression and apocrine differentiation in carcinomas of the breast. Virch Arch 1994;425:459-465.
19. Eusebi V, Foschini MP, Bussolati G, Rosen PP. Myoblastomatoid (histiocytoid) carcinoma of the breast: a type of apocrine carcinoma. Am J Surg Pathol 1995;19:553-562.
20. Soini Y, Kamel D, Nuorova K, Lane DP, Vahakangas K, Paakko P. Low p53 protein expression in salivary gland tumours compared with lung carcinoma. Virch Arch 1992;421:415-420.
21. Deguchi H, Hironori H, Hayashi Y. C-myc, ras p21 and p53 expression in pleomorphic adenoma and its malignant form of the human salivary glands. Acta Pathol Jpn 1993;43:413-422.
22. Felix A, El-Naggar AK, Press MF, et al. Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol 1996;27:561-566.
23. Barnes L, Rao U, Contis L, Krause J, Schwartz A, Scalamonga P. Salivary duct carcinoma: 2, immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin-D, and c-erbB-2 protein. Oral Surg Oral Med Oral Pathol 1994;78:74-80.
24. Hellquist HB, Karlsson MG, Nilsson C. Salivary duct carcinoma: a highly aggressive salivary gland tumour with overexpression of c-erbB-2. J Pathol 1994;172:35-44.
25. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989:58:351-375.
26. Schneider E, Yaw-Huei H, Liu LF. DNA topoisomerases as anticancer drug targets. Adv Pharmacol 1990;21:149-183.
27. Zhang H, D'Arpa PD, Liu LF. A model for tumor cell killing by topoisomerase poisons. Cancer cells 1990;2:23-27.
28. Fisher ER, Palekar AS. Solid and mucinous varieties of so-called mammary carcinoid tumors. Am J Clin Pathol 1997;1:283-292.
29. Gatalica Z. Immunohistochemical analysis of apocrine breast lesions: consistent over-expression of androgen receptors accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol Res Pract 1997;193:753-758.
30. Fan C-Y, Wang J, Barnes LE. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol 2000:24:579-586.